Execute a pivotal program for potential best-in-class BTK degrader, bexobrutideg, including Phase 2 and confirmatory Phase 3 studies to support global registration in relapsed/refractory chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback